RVTY

Business Profile & Competitive Position

Revvity, Inc. (RVTY) is classified in the Healthcare sector under the Medical - Diagnostics & Research industry. The company operates as a health-science solutions provider covering workflows from discovery through development and from diagnosis to cure. Its capabilities include translational multi-omics, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. Revvity reports through two segments: Life Sciences, which supplies reagents, instruments, software, and services to accelerate drug discovery and development, and Diagnostics, which provides instruments, reagents, assay platforms, and software focused on reproductive health, immunodiagnostics, and emerging-market diagnostics. The company markets its products and services in more than 160 countries from its headquarters in Waltham, Massachusetts.

The financial profile sends mixed signals about competitive moat. The net margin is 8.2%, which means the business retains a positive but modest slice of revenue after all costs. More striking is the ROE of 3.3%—a low figure that indicates weak return on shareholder equity despite the company’s specialized scientific positioning. That combination—modest profitability with low capital efficiency—suggests Revvity’s moat is built more on technology breadth, recurring consumables, andacquisition-driven scale than on a high-return, asset-light franchise. It may also reflect heavy reinvestment, integration costs, or capital-intensive instrumentation.

Financial Posture

RVTY currently carries a $14.0 billion market capitalization and trades at a P/E of 59.7. Against an 8.2% net margin and a 3.3% ROE, that multiple is steep: investors are paying nearly 60 times trailing earnings for a company whose current profitability and equity returns are modest by conventional standards. That valuation spread usually implies the market expects earnings growth to accelerate, whether from margin expansion, acquisition synergies, or rising demand for diagnostics and life-science tools.

The stock’s beta is 1.09, meaning it has shown slightly more volatility than the overall market. The current snapshot shows the price at $125.45, with the 50-day EMA at $118.22 and RSI at 55.1. The valuation profile therefore combines a premium multiple with slightly above-market sensitivity, so reported results, guidance, and strategic updates tend to carry outsized weight.

Strategic Priorities & Outlook

Revvity’s most recent 10-K filing outlines four near-term priorities. The first is to strengthen key markets by expanding global product and service offerings, maintaining product quality, and enhancing the customer experience. The second is to accelerate transformational innovation through internal R&D, third-party collaborations, and strategic acquisitions or licensing. The third is to advance the use of Artificial Intelligence to strengthen differentiated offerings and drive internal operating efficiencies. The fourth is to maintain disciplined capital allocation to support organic investment, mergers and acquisitions, and opportunistic share repurchase programs.

These priorities align with the company’s two-segment structure: Life Sciences growth depends on new instruments, reagents, and software workflows, while Diagnostics growth leans on assay platforms and emerging-market expansion. The 10-K also notes that as of December 28, 2025, Revvity employed approximately 11,000 people, including roughly 2,000 sales and service representatives operating in about 40 countries. Products are marketed primarily through specialized sales forces, with distributors used where Revvity does not have direct sales or service presence. A notable operational risk is that certain principal products rely on a limited or single qualified source for critical raw materials and components, and the company periodically buys ahead of manufacturing needs to mitigate that concentration.

Macro & Geopolitical Exposure

As a Medical - Diagnostics & Research company, Revvity is exposed to the regulatory, reimbursement, trade, and supply-chain forces that shape healthcare technology. Diagnostic platforms and reagents face FDA and equivalent overseas approvals, while reimbursement decisions by government payers and private insurers influence adoption speed—particularly in reproductive health and immunodiagnostics. Tariffs or trade restrictions on instruments, components, or specialty chemicals can affect cost structure, especially given the disclosed reliance on limited or single qualified suppliers for some critical inputs.

Currency risk is also material: with sales spread across more than 160 countries, revenue and earnings are subject to foreign-exchange translation effects. The business is further tied to biopharma R&D budgets, academic research funding, and public-health priorities, all of which can shift with fiscal policy and global health spending. Emerging-market diagnostics, listed as a focus area, may carry additional volatility from local regulatory changes and healthcare infrastructure investment cycles.

Recent Developments

• 2026-09-14 — Revvity, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a full transcript published by seekingalpha.com. Conference commentary can set the tone for guidance and capital-allocation messaging before the next earnings release.
• 2026-09-12 — California State Teachers’ Retirement System acquired shares of Revvity, while Amundi trimmed its holdings the same day, according to defenseworld.net. The divergent institutional flows highlight mixed conviction among large asset managers.
• 2026-09-11 — Revvity announced an agreement to acquire Human Cell Design, a move aimed at boosting metabolic discovery capabilities, zacks.com reported. The deal fits the stated strategy of using acquisitions to expand Life Sciences workflows.

Earnings Behavior & Post-Earnings Drift

RVTY has beaten the official consensus in each of the last eight reported quarters, for a 100% beat rate, with an average earnings surprise of 7.2%. The average five-day price move in the trading sessions after earnings across those quarters is 0.8%, classified as an upward drift, but the path has been uneven.

Recent quarters show that beats do not always translate into immediate gains. On August 4, 2026, Revvity reported EPS of $1.41 against an estimate of $1.21—a 16.5% surprise—and the stock rose 3.26% the next day and 3.9% over the following five sessions. On May 5, 2026, EPS of $1.06 beat the $1.02 estimate by 3.9%, producing a 7.36% next-day move and a 7.58% five-day move. By contrast, the February 2, 2026 report of $1.70 versus $1.57 (8.3% surprise) led to a -5.57% next-day drop and a -3.99% five-day drift. The October 27, 2025 report of $1.18 versus $1.14 (3.5% surprise) produced a -0.73% next-day move and a -4.31% five-day drift.

The next scheduled report is October 26, 2026, before the market opens, with the printed consensus EPS estimate at $1.28. Given the 100% beat history, the market’s real expectation may be slightly above that figure, but the stock’s post-release direction will also depend on guidance, margin commentary, and recent M&A integration updates.

For a deeper dive into how institutional analysts are weighing Revvity’s valuation premium, acquisition strategy, and upcoming October 26, 2026 earnings report, explore the full institutional verdict on the trading-analysis platform.